Urgent.News

the world's headlines, one feed

Editions

Health & Medicine

STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer

A rare blood cancer drug from Silence Therapeutics showed strong results in a trial, potentially setting it up to compete with a Takeda medicine.

STAT+: Silence Therapeutics aims at Takeda with new data in rare blood cancer

We haven't written up this one. STAT News has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at statnews.com →

More in Health & Medicine